“The global nutrigenomics market will cross 1,000.0 million revenues by 2030”, says Visiongain

23 January 2020
Pharma

Visiongain’s new report the Nutrigenomics Market Report 2020-2030: Forecasts by Application (Obesity, Cardiovascular Diseases, Cancer Research) plus analysis of leading companies indicates that the global nutrigenomics market will cross 1,000.0 million revenues by 2030.

The worldwide nutrigenomics market is likely to cross USD 1,000.00 million by 2030 recording a CAGR of over 10% over the forecast period. Nutrigenomics research applications for obesity and cancer emerged as market leaders in, and over the forecast period the dominance is expected to continue to grow at a substantial CAGR. Developing regional markets, including Asia Pacific, Latin America and the Middle East, are also projected to expand rapidly due to increased cases of obesity and rising geriatric population.

Noticeable progress in the fields of proteomics, computational biology, metabolic, genomics, and bioinformatics has accelerated the use of nutrigenomics globally exponentially. Nutrigenomics helps to investigate the effect of bioactive dietary elements and nutrients on gene expression as well as to study an individual's inherent risk of disease.  Nutrigenomics can also influence the different parts of a food chain, such as genetic modification of crops and animal feed.

Nutrigenomics is also used in diet design and food safety evaluation. The various advances in nutrigenomics are expected to bring innovation in the field of diet and nutrition, thereby having a positive impact on the overall consumer growth. Furthermore, the support provided by regulatory bodies in numerous countries and the technological developments in the nutrigenomics market would drive the overall growth of this market.

In the years ahead, North America is expected to make a significant contribution to the international nutrigenomics market. This can be due to the release of direct distribution networks for consumer nutrigenomics, the increase of advanced diet consumption, and the implementation of the latest technologies and biotechnologies in the food industry. Therefore, the United States and Canada have a huge number of obese patients and patients with lifestyle-related disorders such as diabetes.

The use of nutrigenomics in the anti-aging field has been made possible by numerous scientific developments. In the form of supplements, numerous customized nutritional solutions are introduced to meet the body's optimal nutritional needs, which impede cell aging by forming numerous free radicals. In addition, by exploring the interaction between genetic factors and dietary patterns, nutrigenomics also offers suggestions on options for preventive treatment or measures for treating obesity through personal nutrition.

It, in effect, will continue to fuel the future growth of this regional market. The Asia Pacific nutrigenomics market is likely to see significant growth in the years ahead due to the increasing demand for healthy foods and beverages that have boosted the adoption of nutrigenomics.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Visiongain Publishes Clinical Perinatal Software Market Report 2020-2030

Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.

01 July 2020

Read

Visiongain publishes Clinical Laboratory Tests Market Report 2020-2030

Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever